The radiosensitizing effect of CpG ODN107 on human glioma cells is tightly related to its antiangiogenic activity via suppression of HIF-1α/ VEGF pathway

International Immunopharmacology

Volumn 17, Issue 2, 2013, Pages 237-244

  Liu, Dan ^a   Cao, Guanqun ^a   Cen, Yanyan ^a   Liu, Tao ^b   Peng, Wei ^a   Sun, Jianguo ^a   Li, Xiaoli ^a   Zhou, Hong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Drug and Equipment Section of 532 Hospital   (China)

Author keywords

Anti angiogenic activity; CpG ODN107; HIF 1 ; Radiosensitivity; VEGF

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE 107; HYPOXIA INDUCIBLE FACTOR 1ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER TRANSPLANTATION; CAPILLARY DENSITY; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ANTI-ANGIOGENIC ACTIVITY; CPG ODN107; HIF-1Α; RADIOSENSITIVITY; VEGF;

ANGIOGENESIS INHIBITORS; ANIMALS; BRAIN NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE, NUDE; MICROVESSELS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGODEOXYRIBONUCLEOTIDES; RADIATION-SENSITIZING AGENTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881489334     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.06.002     Document Type: Article

References (35)

1. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311-33. (Pubitemid 32524640)
2. Pang BC,WanWH, Lee CK, Khu KJ,NgWH. The role of surgery in high-grade glioma- is surgical resection justified? A review of the current knowledge. Ann Acad Med Singapore 2007;36:358-63. (Pubitemid 47121451)
3. Lu Y, Jiang F, Jiang H,Wu K, Zheng X, Cai Y, et al. Gallic acid suppresses cell viability, proliferation, invasion and angiogenesis in human glioma cells. Eur J Pharmacol 2010;641:102-7.
4. Onishi M, Ichikawa T, Kurozumi K, Date I. Angiogenesis and invasion in glioma. Brain Tumor Pathol 2011;28:13-24.
5. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69:11-6. (Pubitemid 41680948)
6. Mason KA, Neal R, Hunter N, Ariga H, Ang K, Milas L. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Radiother Oncol 2006;80:192-8. (Pubitemid 44314019)
7. Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 2010;116:3988-99.
8. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25:4714-21. (Pubitemid 350086472)
9. Chen M, Sun J, Lu C. Inhibitory effect of hypoxia-induced factor-1α ribozyme on the growth of glioma in nude mice. Acad J 2011;6:3045-8.
10. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13. (Pubitemid 26272112)
11. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998;92:2260-8. (Pubitemid 28452966)
12. Safran M, Kaelin Jr WG. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003;111:779-83. (Pubitemid 37074949)
13. Li X, Liu D, Liu X, Jiang W, Zhou W, Yan W, et al. CpG ODN107 potentiates radiosensitivity of human glioma cells via TLR9-mediated NF-kappa B activation and NO production. Tumour Biol 2012;33:1607-18.
14. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002;38: 1564-79. (Pubitemid 34876495)
15. Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 2007;130:3336-41. (Pubitemid 350209077)
16. Azar WJ, Azar SH, Higgins S, Hu JF, Hoffman AR, Newgreen DF, et al. IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. Endocrinology 2011;152:3332-42.
17. Danese S. VEGF in inflammatory bowel disease: a master regulator of mucosal immune-driven angiogenesis. Dig Liver Dis 2008;40:680-3.
18. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:3995-4004. (Pubitemid 32476461)
19. Weiner GJ. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies. Adv Drug Deliv Rev 2009;61:263-7.
20. Yuan S, Qiao T, Chen W. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor. Cancer Biother Radiopharm 2011;26:203-8.
21. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.
22. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009;110:173-80.
23. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12:233-42.
24. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011;29:142-8.
25. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94: 883-93. (Pubitemid 34778087)
26. Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan ST, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002;20:1775-85. (Pubitemid 34273266)
27. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008;7:1152-60.
28. Hilmi C, Guyot M, Pages G. VEGF spliced variants: possible role of anti-angiogenesis therapy. J Nucleic Acids 2012;2012:162692.
29. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 2012;320:130-7.
30. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-71.
31. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
32. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95: 516-25. (Pubitemid 36511622)
33. Fitzpatrick B, Mehibel M, Cowen RL, Stratford IJ. iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 2008;19:217-24.
34. Huang LE, Willmore WG, Gu J, Goldberg MA, Bunn HF. Inhibition of hypoxiainducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J Biol Chem 1999;274:9038-44. (Pubitemid 29164709)
35. Yin JH, Yang DI, Ku G, Hsu CY. iNOS expression inhibits hypoxia-inducible factor-1 activity. Biochem Biophys Res Commun 2000;279:30-4.